Rheumatoid Arthritis

Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.

RA was linked to an increased risk of ischemic and hemorrhagic strokes, with further analysis revealing sex-based differences in stroke outcomes in men vs women with RA.

A study presented at EULAR 2024 found patients with RA of low socioeconomic status have a high prevalence of fatigue.

Compared to patients on stable TNFi, patients tapering TNFi to withdrawal experienced significantly more flares and had lower Boolean 2.0 remission rates.

Positive personality traits and perceived disease impact may play a larger role in explaining sleep disturbances in patients with RA than disease activity, anxiety, or depression.

Patients with RA had a greater risk of delayed cervical cancer screening, and smoking was associated with a decrease in prostate cancer screening in patients with RA.

Presented at EULAR 2024, a study suggested controlling RA disease activity may be important from a psycho-social perspective.

Findings from a 2-year extension of the Plants for Joints randomized controlled trial show promise for the long-term benefits of diet, physical activity, and stress management in RA.

Findings underscore the impact of socioeconomic factors on disease management and therapeutic outcomes in patients with rheumatoid arthritis from different socioeconomic classes.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

A study presented at EULAR 2024 found tender joint count was linked to depression and illness perception but not anxiety.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Phase 3 data showed patients treated with SHR0302 4 mg or 8 mg had greater improvements in ACR20 response rates and other key secondary outcomes versus placebo.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

Some of the risk factors for RA-interstitial lung disease include male sex, older age, and smoking history, a study found.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

A new study found an indirect effect of RA on frailty index through inflammatory cytokines.

An analysis of CDC WONDER data details disparities among the cardiovascular mortality rate for patients with rheumatoid arthritis in the US.

As the severity of rheumatoid arthritis disease activity increases, so does the prevalence of depression, a new study found.

Age, chronic comorbidities, and COVID-19 vaccination status in patients with IMIDs serve as risk factors for severe COVID-19 outcomes.

When the serum cotinine levels were below -2.756 ng/mL, each 1 ng/mL increase in log-2-transformed serum cotinine levels increased the RA risk by 16.3%.